Savara Inc.
1717 Langhorne Newtown Road
Suite 300
Langhorne, PA 19047
United States
(512) 614-1848
https://www.savarapharma.com
版塊: Healthcare
行業: Biotechnology
全職員工: 37
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Matthew Pauls J.D., M.B.A. | Chairman & CEO | 894.54k | 無 | 1971 |
| Mr. David L. Lowrance CPA | CFO, Chief Administrative Officer & Secretary | 613.75k | 無 | 1968 |
| Dr. Raymond Dennis Pratt FACP, M.D. | Chief Medical Officer | 91.89k | 無 | 1951 |
| Mr. Robert Lutz M.B.A. | Chief Operating Officer | 無 | 無 | 1970 |
| Ms. Kate McCabe J.D. | Senior VP & General Counsel | 無 | 無 | 無 |
| Brian Maurer | Head of Clinical Operations | 無 | 無 | 無 |
| Mr. Charles LaPree | Senior Vice President of Global Regulatory Affairs & Quality Assurance | 無 | 無 | 無 |
| Dr. Peter Clarke Ph.D. | Executive Vice President of Global Technical Operations | 無 | 無 | 1960 |
| Mr. Scott L. Wilhoit | Executive Vice President of Global Commercial | 無 | 無 | 1963 |
| Dr. Brian Robinson M.D. | Senior VP of Global Medical Affairs | 無 | 無 | 無 |
截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。
描述
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.
公司管治
截至 2024年4月1日 止，Savara Inc. 的 ISS 管治質素評分為 4。 Pillar 分數正在審核中：4；董事會：6；股東權利：1；現金賠償：7。
企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。
